Search

Your search keyword '"Alhava, E"' showing total 789 results

Search Constraints

Start Over You searched for: Author "Alhava, E" Remove constraint Author: "Alhava, E"
789 results on '"Alhava, E"'

Search Results

301. [Is osteoporosis a disease?].

302. Acute abdominal pain in adults.

303. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.

304. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6.

305. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?

307. Risks of perimenopausal fractures--a prospective population-based study.

308. Expression of C-242 antigen in pancreatic ductal adenocarcinoma.

309. Breathing pattern and gas exchange in emergency and elective abdominal surgical patients.

310. Ultrasound attenuation of the calcaneus in normal subjects and in patients with wrist fracture.

311. Prediction of fracture risk using axial bone mineral density in a perimenopausal population: a prospective study.

312. The effect of gynecological risk factors on lumbar and femoral bone mineral density in peri- and postmenopausal women.

313. The inhibition of CYP enzymes in mouse and human liver by pilocarpine.

315. The long-term outcome after negative appendix operation.

316. [Arteriobiliary fistula as a complication of biliary surgery].

317. Clodronate increases bone mineral density in young growing oophorectomized beagles.

318. Clodronate prevents immobilization osteopenia in rats.

319. Effect of clodronate on fracture healing in denervated rats.

320. The effect of fluoridated drinking water on axial bone mineral density--a population-based study.

321. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma.

322. Bone mineral density and risk factors for osteoporosis--a population-based study of 1600 perimenopausal women.

323. Effects of histamine, H1, H2 and Hic receptor antagonists and alpha-fluoromethylhistidine on the growth of human colorectal cancer in the subrenal capsule assay.

324. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.

325. Sapphire probe versus bare fiber in interstitial laser hyperthermia (ILH). An experimental study with Wistar rats.

326. The effect of previous oral contraceptive use on bone mineral density in perimenopausal women.

327. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma.

328. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.

329. A prospective study on the value of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the diagnosis of unjaundiced cholestasis.

330. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors.

331. Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma.

332. Histomorphometry of periarticular bone in rheumatoid arthritis.

334. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.

335. Phaeochromocytoma in pregnancy.

336. Development of bone mass and bone density of the spine and femoral neck--a prospective study of 65 children and adolescents.

337. Cortical bone mineral density in the mandible and osteoporosis status in postmenopausal women.

338. Trabecular bone mineral density of mandible and alveolar height in postmenopausal women.

339. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.

340. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections.

341. Comparison of classic and quantitative prognostic factors in hormone receptor-positive and hormone receptor-negative female breast cancer.

342. Urinary excretion of polyamines in patients with surgical and accidental trauma: effect of total parenteral nutrition.

343. Nuclear magnetic resonance spectroscopy of plasma to distinguish between malignant and benign diseases causing jaundice and cholestasis.

344. Ag-NORs related to flow cytometry, morphometry and prognosis in patients with pancreatic cancer.

345. A comparison of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the differential diagnosis of benign and malignant jaundice and cholestasis.

346. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.

347. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.

348. Clinical, histological and quantitative prognostic factors in cutaneous malignant melanoma.

349. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.

350. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.

Catalog

Books, media, physical & digital resources